SU873879A3 - Способ получени производных бензимидазола или их солей - Google Patents
Способ получени производных бензимидазола или их солей Download PDFInfo
- Publication number
- SU873879A3 SU873879A3 SU802867805A SU2867805A SU873879A3 SU 873879 A3 SU873879 A3 SU 873879A3 SU 802867805 A SU802867805 A SU 802867805A SU 2867805 A SU2867805 A SU 2867805A SU 873879 A3 SU873879 A3 SU 873879A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- methyl
- hydrogen
- compound
- salts
- methoxy
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims description 7
- 238000000034 method Methods 0.000 title claims description 3
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 title 1
- 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 12
- 239000001257 hydrogen Substances 0.000 claims abstract description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 10
- -1 carbomethoxy, carbethoxy Chemical group 0.000 claims abstract description 9
- 150000002431 hydrogen Chemical class 0.000 claims abstract description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000003647 oxidation Effects 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 230000027119 gastric acid secretion Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 210000004211 gastric acid Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical class C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010016717 Fistula Diseases 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 108010079943 Pentagastrin Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000003890 fistula Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- ANRIQLNBZQLTFV-DZUOILHNSA-N pentagastrin Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1[C]2C=CC=CC2=NC=1)NC(=O)CCNC(=O)OC(C)(C)C)CCSC)C(N)=O)C1=CC=CC=C1 ANRIQLNBZQLTFV-DZUOILHNSA-N 0.000 description 2
- 229960000444 pentagastrin Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- QNOCEOXMZCFKAC-UHFFFAOYSA-N C(=O)(OC)ClC(=O)OCC Chemical compound C(=O)(OC)ClC(=O)OCC QNOCEOXMZCFKAC-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
(54) СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ БЕНЗИМИДАЗОЛА ИЛИ ИХ СОЛЕЙ Изобретение относитс к получению но вых производных бензимицазола, в частности к способу получени производных бензимицазола общей формулы 1 JKT 9Бз,вЛч.5 где Ц в положении 4 означает воцороц или метил, в положении 5- - водород , Метил, метокси, ацетил, карбометокси, карбоэтокси шга хлор; I,j,Rj,Rj, водород или метвл; 1 -водород, метвл, метокси, этокси или 2 -метоксиэтоксй,причем Pg, Н, R могут быть одинаковы шга.различйы, одновременно не означают вбаород, и если два из радикалов Rj, Нд, Rj означают во дород, то третий не означает метил, юга их солей, обладающих тормоз щим выделение кислоты желудочного сока действием . Известен способ получени 2-сульфиниппроизводных бензимидазола, обладающих тормоз щей выделение кислоты желудочного сока активностью, путем окислени соответствующих 2-меркаптопроиЗводных бе нзимиаазола,например м-хлоранабен- зойнойкиспогой.гипохлоридом натри и ap.Lll Цель изобретени - получение новых производных бензимицазола общей формулы 1, обладающих улучшенными по сравнению с известными соей,иненнммигвг йст ами. Поставленна цель достигаетс тем, что согласно способу получени производных бензимидазолд формулы соединение общей. формулы li. I где R и и. . имеют указанные значени , подвергают взаимодейст-вию с соединением общей формулы ;RU где F, F, Rj, и R имеют указанные значени , с послеауюшим окислением получаемого при этом соеаинени и выцепе кием целевого. продукта в свобопном виде шга в вице соли. П р и м е р 1. Смесь из 23,4 г 3,4,5-триметилпириаил-2 -меркаптомурач вьиной кислоты и 16,6 г 4-ацетил 5-метил-о-фениленциамина в 1ОО мл 4 и. хлористовоцородной кислоты кип т т в течение 4О мин. Смесь охлаждают и нейтрализуют аммиаком. Затем нейтральный раствор экстрагируют этилацетатом . Органическую фазу обрабатывают а тивным углем и упаривают в вакууме. Остаток рдаствор ют в ацетоне и затем добавл ют эквивалент концентрированной хлористоводородной кислоты. Оса дающийс гидрохлорид, охлаждают фильтруют и перекристаллизовывают из абсолю ного этанола и простого эфира. Получают 6,5 г гиарохлорива 2-{ 3,4,5-тРиметилпиТаблица 1 ридил)-2-метилмеркапто-5-ацетил-5-метилбензимидазола .Это соединение раствор ют в хлороформе и подвергают окислению м-хлорнадбензойной кислотой при , Осаждаемую м-хлорбензойную кислоту фильтруют и фильтрат разбавл ют, хлористым метиленом , промывают раствором карбоната натри , сушат над сульфатом натри и упаривают в вакууме. После разбавлени ацетонитрилом остаток кристаллизуетс . После перекристаллизации из ацетонитрила получают 2- (3,4,5-триметилпирнаил-2-метилсульфинш: )-5-ацетил-6-метилбензимиаазола с т.пл. i90°C, Примеры 2.30. Аналогично примеру 1 .получают, соединени , сведенные в табл. 1
Продолжение табл. 1
Биологические опыты. Дл определени . степени торможени вы целени кислоты желудочного сока провод т опыты на нб- анестезированных собаках с фистулами, введенными в желудок и двенадцатиперстную кишку. При этом по фистуле, введенной в двенадцатиперстную кишку, подают исследуемые соединени . В начале опытов собакам дают воду в течение 18 ч. Затем собакам делают подкожную инфузию пентагастрина в количестве 1-4 нмоль/ /кг/ч в течение 6-7 ч. Каждые 30 мин собирают пробы желудочного сока. Аликвотную долю каждой пробы титруют ОД н.
цент торможени по сравнению с контрольными опытами. Максимальна степень торможени указана в табл. 2. Исследуемые соединени (в виде суспензии в 0,5% ме- тилцеллюлозы) ввод т в двенадцатиперстную кишку в дозах 4-2О ммоль/кг после достижени посто нного уровн секретного ответа на дачу пентагастрина,
В опытах примен ют предлагаемые и известные соединени , указанные в табл.2.
Ч
Y f ciH-LJ
1- N
«
Claims (1)
- Првмвчавве:х- взвествое соецивбвие 1 Формула изобретени Способ получени производных бенэ имицазола обшей формулы 1 где 1 в пол или метил, в 1 тил, метокси, боэтокси или хлор; . Э 5 6 водород или метил; Кд водород, метил, метокси, этокси или 2-метоксиэтокси, причем % могут быть одинаковы или различны,, одновременно не означают водород, и если два из радикалов К-, 1, Rg- означают в дород, то третий не означает метил, или 9 их солей, отличающийс что соединение общей формулы 11 is, :кНг где К и f(fi имеют указанные значени , подвергают взаимодействию с соединением общей формулы 1ПНц. HOO(i CH-4jjJ . fде Rj R г и F, имеют указанные значени , с последующим окислением получаемого при этом соединени и выделением целевого продукта в свободном виде или в виде соли. Источники информации, прин тые во внимание при экспертизе 1. Авторское свидетельство СССР № 602118, кл. С O7D 401/12, 1975.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE7804231A SE7804231L (sv) | 1978-04-14 | 1978-04-14 | Magsyrasekretionsmedel |
Publications (1)
Publication Number | Publication Date |
---|---|
SU873879A3 true SU873879A3 (ru) | 1981-10-15 |
Family
ID=20334608
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU792751500A SU895292A3 (ru) | 1978-04-14 | 1979-04-13 | Способ получени производных бензимидазола или их солей |
SU802867805A SU873879A3 (ru) | 1978-04-14 | 1980-01-18 | Способ получени производных бензимидазола или их солей |
SU802870598A SU878196A3 (ru) | 1978-04-14 | 1980-01-18 | Способ получени производных бензимидазола или их солей |
SU802870599A SU873880A3 (ru) | 1978-04-14 | 1980-01-18 | Способ получени производных бензимидазола или их солей |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU792751500A SU895292A3 (ru) | 1978-04-14 | 1979-04-13 | Способ получени производных бензимидазола или их солей |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU802870598A SU878196A3 (ru) | 1978-04-14 | 1980-01-18 | Способ получени производных бензимидазола или их солей |
SU802870599A SU873880A3 (ru) | 1978-04-14 | 1980-01-18 | Способ получени производных бензимидазола или их солей |
Country Status (25)
Country | Link |
---|---|
US (3) | US4255431A (ru) |
EP (1) | EP0005129B1 (ru) |
JP (2) | JPS6034956B2 (ru) |
AT (2) | AT389995B (ru) |
BG (1) | BG61492B2 (ru) |
CA (1) | CA1127158A (ru) |
CS (1) | CS261851B2 (ru) |
CY (1) | CY1232A (ru) |
DD (1) | DD142882A5 (ru) |
DE (1) | DE2960293D1 (ru) |
DK (1) | DK150510C (ru) |
FI (1) | FI65067C (ru) |
HK (1) | HK15284A (ru) |
HU (1) | HU179022B (ru) |
IE (1) | IE48370B1 (ru) |
LT (1) | LT2274B (ru) |
LU (2) | LU88305I2 (ru) |
MY (1) | MY8500074A (ru) |
NL (2) | NL930074I2 (ru) |
NO (5) | NO152216C (ru) |
NZ (1) | NZ190203A (ru) |
SE (1) | SE7804231L (ru) |
SG (1) | SG63383G (ru) |
SU (4) | SU895292A3 (ru) |
ZA (1) | ZA791586B (ru) |
Families Citing this family (372)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4359465A (en) * | 1980-07-28 | 1982-11-16 | The Upjohn Company | Methods for treating gastrointestinal inflammation |
CH644116A5 (de) * | 1980-08-21 | 1984-07-13 | Hoffmann La Roche | Imidazolderivate. |
IL66340A (en) * | 1981-08-13 | 1986-08-31 | Haessle Ab | Pharmaceutical compositions comprising pyridylmethyl-thiobenzimidazole derivatives,certain such novel derivatives and their preparation |
JPS58135881A (ja) * | 1981-11-05 | 1983-08-12 | ビク−グルデン・ロムベルク・ヘミツシエ・フアブリク・ゲゼルシヤフト・ミト・ベシユレンクテル・ハフツング | 置換ベンズイミダゾ−ル類、その製造方法と利用、およびこれを含む医薬 |
US4472409A (en) * | 1981-11-05 | 1984-09-18 | Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung | 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects |
DE3216843C2 (de) * | 1982-05-05 | 1986-10-23 | Ludwig Heumann & Co GmbH, 8500 Nürnberg | 3-Thiomethyl-pyridin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
SE8204879D0 (sv) * | 1982-08-26 | 1982-08-26 | Haessle Ab | Novel chemical intermediates |
SE8300736D0 (sv) * | 1983-02-11 | 1983-02-11 | Haessle Ab | Novel pharmacologically active compounds |
SE8301182D0 (sv) * | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
IL71664A (en) * | 1983-05-03 | 1987-11-30 | Byk Gulden Lomberg Chem Fab | Fluoroalkoxy compounds,process for their preparation and pharmaceutical compositions containing the same |
HU191756B (en) * | 1983-05-03 | 1987-04-28 | Byk Gulden Lomberg Chem Fab | Process for preparing new fluoro-alkoxy-benzimidazole derivatives |
CA1259070A (en) * | 1983-07-01 | 1989-09-05 | Upjohn Company (The) | Substituted 2-¬monoannelated(3,4-,4,5-, and 5,6-)- pyridylalkylenesulfinyl|-benzimidazoles |
US5077407A (en) * | 1983-07-01 | 1991-12-31 | The Upjohn Company | Substituted 2-[monoannelated (3,4-,4,5-, and 5,6-) pyridylalkylenesulfinyl]benzimidazoles |
DE3333314A1 (de) * | 1983-09-15 | 1985-03-28 | Hoechst Ag, 6230 Frankfurt | Substituierte pyrido(1,2-c)imidazo(1,2-a)benzimidazole, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen |
US4663347A (en) | 1983-10-31 | 1987-05-05 | Merck Frosst Canada, Inc. | Benzofuran 2-carboxylic acid esters useful as inhibitors of leukotriene biosynthesis |
US4575554A (en) * | 1983-12-05 | 1986-03-11 | The Upjohn Company | Substituted 2-pyridylmethylthio- and sulfinyl-benzimidazoles as gastric antisecretory agents |
ZW4585A1 (en) * | 1984-04-19 | 1985-11-20 | Hoffmann La Roche | Imidazole derivatives |
SE8403179D0 (sv) * | 1984-06-13 | 1984-06-13 | Haessle Ab | New compounds |
IL75400A (en) * | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
EP0174717B1 (en) * | 1984-07-06 | 1992-01-22 | FISONS plc | Benzimidazoles, and their production formulation and use as gastric acid secretion inhibitors |
SE8404065D0 (sv) * | 1984-08-10 | 1984-08-10 | Haessle Ab | Novel biologically active compounds |
JPS6150978A (ja) * | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
JPS6150979A (ja) * | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
US4619997A (en) * | 1984-09-06 | 1986-10-28 | The Upjohn Company | Substituted 2-pyridylmethylthio and sulfinyl-benzimidazoles as gastric antisecretory agents |
KR890000387B1 (ko) * | 1984-09-24 | 1989-03-16 | 디 엎존 캄파니 | 2-(피리딜알켄술 피닐)벤즈 이미드아졸류의 n-치환 유도체의 제조방법 |
SE8405588D0 (sv) * | 1984-11-08 | 1984-11-08 | Haessle Ab | New compounds |
DK585485A (da) * | 1984-12-18 | 1986-08-08 | Utsuka Pharm Co Ltd | Tetrahydroquinolinderivat, imidazopyridinderivat, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat med mindst en saadan forbindelse |
FI861772A (fi) * | 1985-05-07 | 1986-11-08 | Chemie Linz Ag | Nya tieno(2,3-d)imidazolderivat och foerfarande for deras framstaellning. |
US5869513A (en) * | 1985-05-24 | 1999-02-09 | G. D. Searle & Co. | 2- (1H-benzimidazol-2-ylsulfinyl)methyl!benzenamines |
EP0204215B1 (en) | 1985-05-24 | 1993-08-11 | G.D. Searle & Co. | 2-[(1H-benzimidazol-2-ylsulfinyl)methyl]-benzenamines |
CA1309557C (en) | 1985-06-18 | 1992-10-27 | Robert N. Young | Leukotriene antagonists |
US4738975A (en) * | 1985-07-02 | 1988-04-19 | Takeda Chemical Industries, Ltd. | Pyridine derivatives, and use as anti-ulcer agents |
AR243167A1 (es) | 1985-08-24 | 1993-07-30 | Hoechst Ag | Procedimiento para la preparacion de toluidinas sustituidas. |
JPS6261978A (ja) * | 1985-09-12 | 1987-03-18 | Otsuka Pharmaceut Co Ltd | 5−フルオロ−1h−ベンズイミダゾ−ル誘導体 |
SE8505112D0 (sv) * | 1985-10-29 | 1985-10-29 | Haessle Ab | Novel pharmacological compounds |
CA1327010C (en) * | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
US5433959A (en) | 1986-02-13 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
US6749864B2 (en) * | 1986-02-13 | 2004-06-15 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
DE3777855D1 (de) | 1986-02-20 | 1992-05-07 | Hoechst Ag | Substituierte thienoimidazol-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung als magensaeuresekretionshemmer. |
WO1987005296A1 (en) * | 1986-03-07 | 1987-09-11 | Pfizer Inc. | 2-[(2-pyridyl)methylsulfinyl]thienoimidazoles and related compounds as antiulcer agents |
EP0239306B1 (en) | 1986-03-27 | 1993-06-02 | Merck Frosst Canada Inc. | Tetrahydrocarbazole esters |
GB2189698A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
US4687775A (en) * | 1986-07-17 | 1987-08-18 | G. D. Searle & Co. | 2-[(Imidazo[1,2-a]pyridinylmethyl)sulfinyl]-1H-benzimidazoles |
US4772619A (en) * | 1986-07-17 | 1988-09-20 | G. D. Searle & Co. | [(1H-benzimidazol-2-ylsulfinyl)methyl]-2-pyridinamines |
US4721718A (en) * | 1986-08-18 | 1988-01-26 | G. D. Searle & Co. | 2-[(imidazo[1,2-a]pyridin-3-ylmethyl)sulfinyl]-1H-benzimidazoles useful in the treatment and prevention of ulcers |
CA1256109A (en) * | 1986-09-10 | 1989-06-20 | Franz Rovenszky | Process for the preparation of derivatives of 4, 5-dihydrooxazoles |
SE8604566D0 (sv) * | 1986-10-27 | 1986-10-27 | Haessle Ab | Novel compunds |
ATE103912T1 (de) * | 1986-11-13 | 1994-04-15 | Eisai Co Ltd | Pyridin-derivate, deren pharmazeutische zusammenstellungen, deren anwendung fuer die herstellung von arzneimitteln mit therapeutischem oder vorbeugendem wert und verfahren zu deren herstellung. |
FI90544C (fi) * | 1986-11-13 | 1994-02-25 | Eisai Co Ltd | Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi |
SE8604998D0 (sv) | 1986-11-21 | 1986-11-21 | Haessle Ab | Novel pharmacological compounds |
NZ222495A (en) | 1986-11-21 | 1991-04-26 | Haessle Ab | Benzimidazole derivatives and pharmaceutical compositions |
DE3639926A1 (de) * | 1986-11-22 | 1988-06-01 | Hoechst Ag | Substituierte thienoimidazoltoluidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung als magensaeuresekretionshemmer |
FI91754C (fi) * | 1986-12-02 | 1994-08-10 | Tanabe Seiyaku Co | Analogiamenetelmä lääkeaineena käyttökelpoisen imidatsolijohdannaisen valmistamiseksi |
JPS63230633A (ja) * | 1987-03-19 | 1988-09-27 | Nippon Chemiphar Co Ltd | 胃腸の細胞保護剤 |
DE3719783A1 (de) * | 1987-06-13 | 1988-12-22 | Hoechst Ag | Verfahren zur herstellung von 5-phenylsulfinyl-1h-2-(methoxycarbonylamino)- benzimidazol |
FI96860C (fi) * | 1987-06-17 | 1996-09-10 | Eisai Co Ltd | Analogiamenetelmä lääkeaineena käytettävän pyridiinijohdannaisen valmistamiseksi |
JP2718945B2 (ja) * | 1987-06-17 | 1998-02-25 | エーザイ株式会社 | ピリジン誘導体及びそれを含有する潰瘍治療剤 |
DE3723327A1 (de) * | 1987-07-15 | 1989-02-02 | Hoechst Ag | Substituierte thienoimidazol-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung als magensaeuresekretionshemmer, magenschutzmittel sowie als medikament gegen intestinale entzuendungen |
DK171989B1 (da) * | 1987-08-04 | 1997-09-08 | Takeda Chemical Industries Ltd | Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler |
EP0425505B1 (en) * | 1988-06-30 | 1993-03-17 | The Upjohn Company | Transdermal antisecretory agents for gastrointestinal disease |
US5223515A (en) * | 1988-08-18 | 1993-06-29 | Takeda Chemical Industries, Ltd. | Injectable solution containing a pyridyl methylsulfinylbenzimidazole |
AU4057189A (en) * | 1988-08-23 | 1990-03-23 | Aktiebolaget Hassle | Treatment of glaucoma and related disorders in the human eye with pyridinylmethyl (sulfinyl or thio)benzimidazoles |
US5075323A (en) * | 1988-08-24 | 1991-12-24 | Aktiebolaget Hassle | Compounds including omeprazole in the treatment of glaucoma |
WO1990003373A1 (en) * | 1988-09-20 | 1990-04-05 | Hisamitsu Pharmaceutical Co., Inc. | NOVEL DIBENZ[b,e]OXEPIN DERIVATIVES |
AT391693B (de) * | 1988-11-15 | 1990-11-12 | Cl Pharma | Verfahren zur herstellung von 3-5-dimethyl-4methoxypyridinderivaten sowie neues zwischenprodukt hierfuer |
SE8804628D0 (sv) | 1988-12-22 | 1988-12-22 | Ab Haessle | New compounds |
EG19302A (en) * | 1988-12-22 | 1994-11-30 | Haessle Ab | Compound with gastric acid inhibitory effect and process for its preparation |
SE8804629D0 (sv) | 1988-12-22 | 1988-12-22 | Ab Haessle | New therapeutically active compounds |
JP2694361B2 (ja) * | 1989-02-09 | 1997-12-24 | アストラ アクチエボラグ | 抗菌剤 |
GB2239453A (en) * | 1989-11-27 | 1991-07-03 | Haessle Ab | Omeprazole |
US4965269A (en) * | 1989-12-20 | 1990-10-23 | Ab Hassle | Therapeutically active chloro substituted benzimidazoles |
US5274099A (en) * | 1989-12-20 | 1993-12-28 | Aktiebolaget Hassle | Therapeutically active fluoro substituted benzimidazoles |
US5049674A (en) * | 1989-12-20 | 1991-09-17 | Aktiebolaget Hassle | Therapeutically active fluoro substituted benzimidazoles |
KR930000861B1 (ko) * | 1990-02-27 | 1993-02-08 | 한미약품공업 주식회사 | 오메프라졸 직장투여 조성물 |
BR9106309A (pt) | 1990-04-04 | 1993-04-20 | Chiron Corp | Combinacao de antigenos sinteticos de hepatite c viral (hcv),processo de detectar anticorpos para o virus da hepatite c e estojo para realizar teste |
SE9002043D0 (sv) * | 1990-06-07 | 1990-06-07 | Astra Ab | Improved method for synthesis |
SE9002206D0 (sv) | 1990-06-20 | 1990-06-20 | Haessle Ab | New compounds |
ES2140391T3 (es) * | 1990-06-20 | 2000-03-01 | Astra Ab | Derivados de dialcoxi-piridinil-bencimidazol, procedimiento para su preparacion y su uso farmaceutico. |
US5061805A (en) * | 1990-08-10 | 1991-10-29 | Reilly Industries, Inc. | Process for preparing 2-methyl-3,5-dialkylpyridines by dealkylation with sulfur |
CA2052698A1 (en) * | 1990-10-11 | 1992-04-12 | Roger G. Berlin | Treatment of peptic ulcer |
CA2053216C (en) | 1990-10-12 | 2003-04-08 | Michel L. Belley | Saturated hydroxyalkylquinoline acids as leukotriene antagonists |
DE69132082T2 (de) * | 1990-10-17 | 2000-08-31 | Takeda Chemical Industries, Ltd. | Pyridin-Derivate, Verfahren zu deren Herstellung und Anwendung |
ES2026761A6 (es) * | 1990-10-31 | 1992-05-01 | Genesis Para La Investigacion | Procedimiento de obtencion del omeprazol. |
NZ244301A (en) * | 1991-09-20 | 1994-08-26 | Merck & Co Inc | Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds |
FR2692146B1 (fr) * | 1992-06-16 | 1995-06-02 | Ethypharm Sa | Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention. |
HUT71885A (en) * | 1992-07-08 | 1996-02-28 | Monsanto Co | Process for preparing a composition containing benzimidazoles for treatment stomach ulcer in swine |
US5589491A (en) * | 1992-07-28 | 1996-12-31 | Astra Aktiebolag | Injection and injection kit containing omeprazole and its analogs |
US6875872B1 (en) | 1993-05-28 | 2005-04-05 | Astrazeneca | Compounds |
SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
SE9302395D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
SE9302396D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
US5410054A (en) * | 1993-07-20 | 1995-04-25 | Merck Frosst Canada, Inc. | Heteroaryl quinolines as inhibitors of leukotriene biosynthesis |
TW280770B (ru) | 1993-10-15 | 1996-07-11 | Takeda Pharm Industry Co Ltd | |
KR960705811A (ko) * | 1993-10-29 | 1996-11-08 | 고오야 다다시 | 피리딘 화합물 및 그의 약학적 용도[pyridine compound and medicinal use thereof] |
US5374730A (en) * | 1993-11-04 | 1994-12-20 | Torcan Chemical Ltd. | Preparation of omeprazole and lansoprazole |
US5502195A (en) * | 1993-11-04 | 1996-03-26 | Slemon; Clarke | Sulfoxide-carboxylate intermediates of omeprazole and lansoprazole |
KR0142815B1 (ko) * | 1994-12-02 | 1998-07-15 | 정도언 | 신규한 5-피롤릴-6-할로게노-2피리딜메틸설피닐벤즈이미다졸 유도체 |
KR0179401B1 (ko) * | 1994-02-28 | 1999-03-20 | 송택선 | 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체 |
AU2395095A (en) | 1994-04-29 | 1995-11-29 | G.D. Searle & Co. | Method of using (h+/k+) atpase inhibitors as antiviral agents |
SK283626B6 (sk) | 1994-07-08 | 2003-10-07 | Astrazeneca Ab | Multijednotková tabletovaná dávková forma, spôsob jej prípravy a jej použitie |
SE9402431D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
SE504459C2 (sv) * | 1994-07-15 | 1997-02-17 | Astra Ab | Förfarande för framställning av substituerade sulfoxider |
GB9423968D0 (en) * | 1994-11-28 | 1995-01-11 | Astra Ab | Resolution |
GB9423970D0 (en) * | 1994-11-28 | 1995-01-11 | Astra Ab | Oxidation |
SE9500422D0 (sv) * | 1995-02-06 | 1995-02-06 | Astra Ab | New oral pharmaceutical dosage forms |
SE9500478D0 (sv) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
JP3015702B2 (ja) * | 1995-02-21 | 2000-03-06 | 株式会社アラクス | イミダゾール誘導体及びそれらの薬剤として許容される酸付加塩及びその製造法並びにそれらを有効成分とする抗潰瘍剤 |
JP3046924B2 (ja) * | 1995-03-27 | 2000-05-29 | 株式会社アラクス | イミダゾリン誘導体又はそれらの可能な互変異性体及びそれらの製造方法並びにそれらを有効成分とする創傷治療薬 |
US5708017A (en) * | 1995-04-04 | 1998-01-13 | Merck & Co., Inc. | Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors |
HRP960232A2 (en) * | 1995-07-03 | 1998-02-28 | Astra Ab | A process for the optical purification of compounds |
US5686588A (en) * | 1995-08-16 | 1997-11-11 | Yoo; Seo Hong | Amine acid salt compounds and process for the production thereof |
US5824339A (en) * | 1995-09-08 | 1998-10-20 | Takeda Chemical Industries, Ltd | Effervescent composition and its production |
HU227566B1 (en) * | 1995-09-21 | 2011-08-29 | Pharma Pass Llc | Acid-labile pharmaceutical composition containing omeprazole and process for its preparation |
SE521100C2 (sv) * | 1995-12-15 | 2003-09-30 | Astra Ab | Förfarande för framställning av en bensimidazolförening |
KR970032861A (ko) * | 1995-12-29 | 1997-07-22 | 김준웅 | 헬리코박터 피로리 제거용 약제 투여방법 |
US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US20050054682A1 (en) * | 1996-01-04 | 2005-03-10 | Phillips Jeffrey O. | Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same |
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
SE9600070D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
AU1538397A (en) * | 1996-02-06 | 1997-08-28 | Pdi-Research Laboratories, Inc. | Synthesis of omeprazole-type pyridine derivatives and intermediates thereof |
US6623759B2 (en) | 1996-06-28 | 2003-09-23 | Astrazeneca Ab | Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof |
US5625069A (en) * | 1996-07-22 | 1997-04-29 | Development Center For Biotechnology | Process for preparing 2-cyano-3,5-dimethyl-4-methoxypyridine |
US6599927B2 (en) | 1996-10-11 | 2003-07-29 | Astrazeneca Ab | Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome |
TW385306B (en) * | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
SE510666C2 (sv) * | 1996-12-20 | 1999-06-14 | Astra Ab | Nya Kristallmodifikationer |
CA2204580A1 (en) * | 1997-05-06 | 1998-11-06 | Michel Zoghbi | Synthesis of pharmaceutically useful pyridine derivatives |
US6437139B1 (en) | 1997-05-06 | 2002-08-20 | Pdi-Research Laboratories, Inc. | Synthesis of pharmaceutically useful pyridine derivatives |
KR100463031B1 (ko) * | 1997-05-26 | 2005-04-06 | 동아제약주식회사 | 5-메톡시-2-[3,5-디메틸-4-메톡시피리딜메틸)설피닐]-1h-벤즈이미다졸의신규제조방법 |
SE9702000D0 (sv) * | 1997-05-28 | 1997-05-28 | Astra Ab | New pharmaceutical formulation |
JP2002510293A (ja) * | 1997-05-30 | 2002-04-02 | ドクター・レディーズ・リサーチ・ファウンデーション | 抗潰瘍剤として新規なベンゾイミダゾール誘導体、それらの製造方法、及びそれらを含有する薬学的組成物 |
SE510650C2 (sv) | 1997-05-30 | 1999-06-14 | Astra Ab | Ny förening |
US6747155B2 (en) | 1997-05-30 | 2004-06-08 | Astrazeneca Ab | Process |
SE510643C2 (sv) | 1997-06-27 | 1999-06-14 | Astra Ab | Termodynamiskt stabil omeprazol natrium form B |
US6313303B1 (en) * | 1997-07-11 | 2001-11-06 | Eisai Co., Ltd. | Process for the preparation of pyridine derivatives |
SI9700186B (sl) * | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin |
AU9067198A (en) | 1997-07-25 | 1999-02-16 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Proton pump inhibitor in therapeutic combination with antibacterial substances |
US6296876B1 (en) | 1997-10-06 | 2001-10-02 | Isa Odidi | Pharmaceutical formulations for acid labile substances |
US7230014B1 (en) * | 1997-10-14 | 2007-06-12 | Eisai Co., Ltd. | Pharmaceutical formulation comprising glycine as a stabilizer |
SE9704183D0 (sv) * | 1997-11-14 | 1997-11-14 | Astra Ab | New process |
US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
US6174548B1 (en) | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
AU751066B2 (en) | 1997-12-08 | 2002-08-08 | Nycomed Gmbh | Novel administration form comprising an acid-labile active compound |
DE19754324A1 (de) * | 1997-12-08 | 1999-06-10 | Byk Gulden Lomberg Chem Fab | Neue Darreichungsform enthaltend einen säurelabilen Wirkstoff |
SE9704870D0 (sv) | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
SE9704869D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
US6159968A (en) * | 1998-01-15 | 2000-12-12 | University Of Cincinnati | Activation of chloride channels for correction of defective chloride transport |
US6350876B2 (en) | 1998-01-26 | 2002-02-26 | Kuraray Co., Ltd. | 4-chloro-3,5-dimethyl-2-sulfonyl pyridines |
KR100396431B1 (ko) * | 1998-01-26 | 2003-09-02 | 가부시키가이샤 구라레 | 2-술포닐피리딘 유도체 및 2-[((2-피리딜)메틸)티오]-1h-벤즈이 |
IT1299198B1 (it) * | 1998-03-05 | 2000-02-29 | Nicox Sa | Sali nitrati di farmaci antiulcera |
KR100554924B1 (ko) | 1998-05-18 | 2006-03-03 | 다케다 야쿠힌 고교 가부시키가이샤 | 구강내 붕괴 정제 |
US6303787B1 (en) | 1998-05-27 | 2001-10-16 | Natco Pharma Limited | Intermediates and an improved process for the preparation of Omeprazole employing the said intermediates |
ZA9810765B (en) * | 1998-05-28 | 1999-08-06 | Ranbaxy Lab Ltd | Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole. |
AU4387799A (en) * | 1998-06-26 | 2000-01-17 | Russinsky Limited | Pyridine building blocks as intermediates in the synthesis of pharmaceutically active compounds |
SI20019A (sl) | 1998-07-13 | 2000-02-29 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola |
ES2192394T3 (es) | 1998-08-10 | 2003-10-01 | Winston Pharmateuticals Llc | Profarmacos de inhibidores de la bomba de protones. |
US6093734A (en) * | 1998-08-10 | 2000-07-25 | Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin | Prodrugs of proton pump inhibitors |
US6166213A (en) * | 1998-08-11 | 2000-12-26 | Merck & Co., Inc. | Omeprazole process and compositions thereof |
US6191148B1 (en) | 1998-08-11 | 2001-02-20 | Merck & Co., Inc. | Omerazole process and compositions thereof |
PT1105105E (pt) | 1998-08-12 | 2006-07-31 | Altana Pharma Ag | Forma de administracao oral para piridin-2-ilmetilsulfinil-1h-benzimidazois |
DE19843413C1 (de) * | 1998-08-18 | 2000-03-30 | Byk Gulden Lomberg Chem Fab | Neue Salzform von Pantoprazol |
US6733778B1 (en) * | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
SE9803772D0 (sv) | 1998-11-05 | 1998-11-05 | Astra Ab | Pharmaceutical formulation |
AU1054899A (en) * | 1998-11-06 | 2000-05-29 | Dong-A Pharmaceutical Co., Ltd. | Method of preparing sulfide derivatives |
IL142703A (en) | 1998-11-10 | 2006-04-10 | Astrazeneca Ab | Crystalline form of omeprazole |
UA72748C2 (en) * | 1998-11-10 | 2005-04-15 | Astrazeneca Ab | A novel crystalline form of omeprazole |
JP3926936B2 (ja) | 1998-11-16 | 2007-06-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | スルホキシド誘導体・アセトン錯体およびその製造法 |
SE9900274D0 (sv) | 1999-01-28 | 1999-01-28 | Astra Ab | New compound |
US6852739B1 (en) * | 1999-02-26 | 2005-02-08 | Nitromed Inc. | Methods using proton pump inhibitors and nitric oxide donors |
TWI243672B (en) | 1999-06-01 | 2005-11-21 | Astrazeneca Ab | New use of compounds as antibacterial agents |
IL146504A0 (en) | 1999-06-07 | 2002-07-25 | Byk Gulden Lomberg Chem Fab | Pharmaceutical compositions containing an acid-labile active compound and processes for the preparation thereof |
IL130602A0 (en) | 1999-06-22 | 2000-06-01 | Dexcel Ltd | Stable benzimidazole formulation |
US6555139B2 (en) | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
US6245913B1 (en) | 1999-06-30 | 2001-06-12 | Wockhardt Europe Limited | Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole |
EP1206263A1 (en) * | 1999-08-26 | 2002-05-22 | aaiPharma Inc. | Ft-raman spectroscopic measurement of omeprazole isomer ratio in a composition |
US6312723B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6369087B1 (en) * | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
CA2382867A1 (en) * | 1999-08-26 | 2001-03-01 | Applied Analytical Industries, Inc. | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6268385B1 (en) | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
EP1595879A3 (en) * | 1999-08-26 | 2010-01-27 | aaiPharma Inc. | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6326384B1 (en) | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
US6262086B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
US6780880B1 (en) | 1999-08-26 | 2004-08-24 | Robert R. Whittle | FT-Raman spectroscopic measurement |
US6262085B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
US6312712B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
US6316020B1 (en) | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
US6228400B1 (en) | 1999-09-28 | 2001-05-08 | Carlsbad Technology, Inc. | Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same |
SE9903831D0 (sv) * | 1999-10-22 | 1999-10-22 | Astra Ab | Formulation of substituted benzimidazoles |
DE19951960C2 (de) * | 1999-10-28 | 2002-06-27 | Gruenenthal Gmbh | Verfahren zur Herstellung als Ulkustherapeutika geeigneter Benzimidazol-Derivate |
CA2290893C (en) | 1999-11-16 | 2007-05-01 | Bernard Charles Sherman | Magnesium omeprazole |
DE19959419A1 (de) | 1999-12-09 | 2001-06-21 | Ratiopharm Gmbh | Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung |
AU2583901A (en) * | 1999-12-17 | 2001-06-25 | Ariad Pharmaceuticals, Inc. | Proton pump inhibitors |
US6787342B2 (en) | 2000-02-16 | 2004-09-07 | Merial Limited | Paste formulations |
SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
SE0000774D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
US6306435B1 (en) | 2000-06-26 | 2001-10-23 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same |
SE0002476D0 (sv) | 2000-06-30 | 2000-06-30 | Astrazeneca Ab | New compounds |
US6544556B1 (en) | 2000-09-11 | 2003-04-08 | Andrx Corporation | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
US20020064555A1 (en) * | 2000-09-29 | 2002-05-30 | Dan Cullen | Proton pump inhibitor formulation |
KR20030059318A (ko) | 2000-12-07 | 2003-07-07 | 알타나 파마 아게 | 산 불안정성 활성 성분을 포함하는 현탁액 형태의 약학 제제 |
CA2430816C (en) | 2000-12-07 | 2012-05-15 | Altana Pharma Ag | Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient |
EP1341528B1 (en) | 2000-12-07 | 2012-01-18 | Nycomed GmbH | Rapidly disintegrating tablet comprising an acid-labile active ingredient |
KR20040029966A (ko) | 2001-02-02 | 2004-04-08 | 테바 파마슈티컬 인더스트리즈 리미티드 | 치환된 2-(2-피리딜메틸)설피닐-1h-벤즈이미다졸 |
US6645946B1 (en) | 2001-03-27 | 2003-11-11 | Pro-Pharmaceuticals, Inc. | Delivery of a therapeutic agent in a formulation for reduced toxicity |
SE0101379D0 (sv) * | 2001-04-18 | 2001-04-18 | Diabact Ab | Komposition som hämmar utsöndring av magsyra |
SI20875A (sl) * | 2001-04-25 | 2002-10-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Kristalna oblika omeprazola |
US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
MXPA03011017A (es) * | 2001-06-01 | 2005-04-29 | Pozen Inc | Composiciones farmaceuticas para la entrega coordinada de nsaids. |
DE10140492A1 (de) | 2001-08-17 | 2003-08-14 | Gruenenthal Gmbh | Hydrate von gegebenenfalls substituierten 2-(2-Pyridinyl)methylthio-1H-benzimidazolen und Verfahren zu ihrer Herstellung |
SE0102993D0 (sv) | 2001-09-07 | 2001-09-07 | Astrazeneca Ab | New self emulsifying drug delivery system |
AU2002332178B2 (en) * | 2001-09-18 | 2005-12-08 | Zeria Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
DK1459737T3 (da) | 2001-10-17 | 2013-01-02 | Takeda Pharmaceutical | Granulat indeholdende syreustabilt kemisk middel i stor mængde |
US7855082B1 (en) | 2001-10-31 | 2010-12-21 | Astrazeneca Ab | Raman spectroscopic method for determining the ratio of 5-methoxy and 6-methoxy isomers of omeprazole |
CA2472103A1 (en) * | 2002-01-25 | 2003-08-07 | Santarus, Inc. | Transmucosal delivery of proton pump inhibitors |
ES2286408T3 (es) | 2002-03-05 | 2007-12-01 | Astrazeneca Ab | Sales de alquilamonio de omeprazol e esomeprazol. |
PT1492511E (pt) | 2002-04-09 | 2009-04-09 | Flamel Tech Sa | Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s) |
BR0309093A (pt) | 2002-04-09 | 2005-02-09 | Flamel Tech Sa | Formulação farmacêutica oral sob a forma de suspensão aquosa de microcápsulas permitindo a liberação modificada de amoxicilina |
US20030228363A1 (en) * | 2002-06-07 | 2003-12-11 | Patel Mahendra R. | Stabilized pharmaceutical compositons containing benzimidazole compounds |
US20040034078A1 (en) * | 2002-06-14 | 2004-02-19 | Agouron Pharmaceuticals, Inc. | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase |
KR100788778B1 (ko) * | 2002-07-19 | 2007-12-27 | 윈스턴 파마슈티컬즈, 엘엘씨 | 벤즈이미다졸 유도체 및 이들의 프로톤 펌프 억제제의프로드럭으로서의 이용 |
TW200410955A (en) | 2002-07-29 | 2004-07-01 | Altana Pharma Ag | Novel salt of (S)-PANTOPRAZOLE |
CA2493618A1 (en) * | 2002-08-01 | 2004-02-12 | Nitromed, Inc. | Nitrosated proton pump inhibitors, compositions and methods of use |
MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
SE0203065D0 (sv) | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
ES2534713T3 (es) | 2002-10-16 | 2015-04-27 | Takeda Pharmaceutical Company Limited | Preparaciones sólidas estables |
SE0203092D0 (en) * | 2002-10-18 | 2002-10-18 | Astrazeneca Ab | Method for the synthesis of a benzimidazole compound |
FR2845915B1 (fr) | 2002-10-21 | 2006-06-23 | Negma Gild | Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien |
BR0315574A (pt) * | 2002-10-22 | 2005-09-20 | Ranbaxy Lab Ltd | Forma amorfa de esomeprazol, composição farmacêutica contendo o mesmo e processo para sua preparação |
DE10254167A1 (de) | 2002-11-20 | 2004-06-09 | Icon Genetics Ag | Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen |
KR101062806B1 (ko) | 2002-12-06 | 2011-09-07 | 니코메드 게엠베하 | 광학적으로 순수한 활성 화합물의 제조 방법 |
EP1575941B1 (en) | 2002-12-06 | 2012-04-11 | Nycomed GmbH | Process for preparing (S)-pantoprazole |
FR2848555B1 (fr) | 2002-12-16 | 2006-07-28 | Negma Gild | Enantiomere(-)du tenatoprazole et son application en therapeutique |
JP2006514108A (ja) * | 2002-12-19 | 2006-04-27 | テバ ファーマシューティカル インダストリーズ リミティド | パントプラゾールナトリウムの固体状態、それらの調製方法、及び公知のパントプラゾールナトリウム水和物の調製方法 |
US20040166162A1 (en) * | 2003-01-24 | 2004-08-26 | Robert Niecestro | Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid |
CA2517005A1 (en) * | 2003-02-20 | 2004-09-02 | Santarus, Inc. | A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
US20040185119A1 (en) * | 2003-02-26 | 2004-09-23 | Theuer Richard C. | Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency |
EP1601667A2 (en) * | 2003-03-12 | 2005-12-07 | Teva Pharmaceutical Industries Limited | Crystalline and amorphous solids of pantoprazole and processes for their preparation |
US7608625B2 (en) * | 2003-03-13 | 2009-10-27 | Eisai R & D Management Co., Ltd. | Method for treating bruxism and bruxism-related diseases |
US20040185092A1 (en) * | 2003-03-18 | 2004-09-23 | Yih Ming Hsiao | Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use |
WO2004087702A2 (fr) * | 2003-03-28 | 2004-10-14 | Sidem Pharma | Procede de preparation enantioselective de derives de sulfoxydes. |
FR2852956B1 (fr) * | 2003-03-28 | 2006-08-04 | Negma Gild | Procede de preparation enantioselective de derives de sulfoxydes |
PE20050150A1 (es) | 2003-05-08 | 2005-03-22 | Altana Pharma Ag | Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo |
CL2004000983A1 (es) | 2003-05-08 | 2005-03-04 | Altana Pharma Ag | Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y |
US7524837B2 (en) * | 2003-05-12 | 2009-04-28 | Janssen Pharmaceutica N.V. | Benzotriazapinone salts and methods for using same |
US7683177B2 (en) * | 2003-06-10 | 2010-03-23 | Teva Pharmaceutical Industries Ltd | Process for preparing 2-[(pyridinyl)methyl]sulfinyl-substituted benzimidazoles and novel chlorinated derivatives of pantoprazole |
US8802139B2 (en) | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
BRPI0412590A (pt) * | 2003-07-15 | 2006-09-19 | Allergan Inc | processo para preparação de pró-drogas isomericamente puras de inibidores de bomba de próton |
CA2531566C (en) * | 2003-07-18 | 2013-05-07 | Santarus, Inc. | Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
JP2006528181A (ja) * | 2003-07-18 | 2006-12-14 | サンタラス インコーポレイティッド | 酸分泌を阻害するために有用な薬学的製剤ならびにそれらを作製および使用する方法 |
AU2004268383A1 (en) * | 2003-09-03 | 2005-03-10 | Agi Therapeutics Limited | Proton pump inhibitor formulations, and methods of preparing and using such formulations |
SE0302381D0 (sv) | 2003-09-04 | 2003-09-04 | Astrazeneca Ab | New salts I |
SE0302382D0 (sv) | 2003-09-04 | 2003-09-04 | Astrazeneca Ab | New salts II |
TWI372066B (en) | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
US20050075371A1 (en) * | 2003-10-03 | 2005-04-07 | Allergan, Inc. | Methods and compositions for the oral administration of prodrugs of proton pump inhibitors |
US20060241037A1 (en) * | 2003-10-03 | 2006-10-26 | Allergan Inc. | Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump ihhibitor prodrugs |
RU2006117793A (ru) * | 2003-10-24 | 2007-12-10 | Иммунэйд Пти Лтд. (Au) | Способ лечения |
US20070292498A1 (en) * | 2003-11-05 | 2007-12-20 | Warren Hall | Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers |
WO2005077936A1 (en) | 2004-02-11 | 2005-08-25 | Ulkar Kimya Sanayii Ve Ticaret A.S. | Pyridine benzimidazole sulfoxides with high purity |
US20070161679A1 (en) * | 2004-02-18 | 2007-07-12 | Allergan, Inc. | Method and compositions for the intravenous administration of compounds related to proton pump inhibitors |
EP1715861A2 (en) * | 2004-02-18 | 2006-11-02 | Allergan, Inc. | Compositions comprising prodrugs of proton pump inhibitors |
SE0400410D0 (sv) | 2004-02-20 | 2004-02-20 | Astrazeneca Ab | New compounds |
US20080287502A1 (en) * | 2004-03-30 | 2008-11-20 | Dermatrends, Inc. | Transdermal Administration of Proton Pump Inhibitors |
DK1740571T3 (da) | 2004-04-28 | 2009-11-02 | Hetero Drugs Ltd | Fremgangsmåde til fremstilling af pyridinylmethyl-1H-benzimidazolforbindelser i enantiomerisk beriget form eller som enkelte enantiomerer |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
US20050267157A1 (en) * | 2004-05-28 | 2005-12-01 | David White | Magnesium-S-omeprazole |
PT1748998E (pt) | 2004-05-28 | 2010-03-24 | Hetero Drugs Ltd | Novo processo de síntese estereoselectiva de sulfóxidos de benzimidazol |
CA2568652A1 (en) * | 2004-06-02 | 2005-12-15 | Altana Pharma Ag | Process for the preparation of pyridin-2-ylmethylsulphinyl-1h-benzimidazol compounds |
US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
US20060024362A1 (en) * | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
CN102775388B (zh) | 2004-09-13 | 2016-01-20 | 武田药品工业株式会社 | 氧化化合物的制备方法和制备装置 |
US8541026B2 (en) | 2004-09-24 | 2013-09-24 | Abbvie Inc. | Sustained release formulations of opioid and nonopioid analgesics |
KR20070109985A (ko) | 2004-11-22 | 2007-11-15 | 아나디스 리미티드 | 생물활성 조성물 |
WO2006067599A2 (en) | 2004-12-23 | 2006-06-29 | Ranbaxy Laboratories Limited | Stable oral benzimidazole compositions and process of preparation thereof |
WO2006087613A2 (en) * | 2005-02-02 | 2006-08-24 | Ranbaxy Laboratories Limited | Stable oral benzimidazole compositions prepared by non-aqueous layering process |
WO2006090845A1 (ja) | 2005-02-25 | 2006-08-31 | Takeda Pharmaceutical Company Limited | 顆粒の製造方法 |
US7803817B2 (en) | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
US7981908B2 (en) | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
EP1891043A1 (en) | 2005-06-15 | 2008-02-27 | Hetero Drugs Limited | Amorphous esomeprazole hydrate |
WO2007004236A2 (en) | 2005-07-04 | 2007-01-11 | Ramu Krishnan | Improved drug or pharmaceutical compounds and a preparation thereof |
EP1904064A4 (en) * | 2005-07-07 | 2009-12-02 | Reddys Lab Ltd Dr | OMEPRAZOLE OF FORM B |
US7601737B2 (en) * | 2005-07-26 | 2009-10-13 | Nycomed Gmbh | Isotopically substituted proton pump inhibitors |
JP5289951B2 (ja) * | 2005-07-26 | 2013-09-11 | タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 同位体置換されたパントプラゾール |
NZ565078A (en) * | 2005-07-26 | 2010-03-26 | Nycomed Gmbh | Deuterated proton pump inhibitors such as omeprazole |
JP2009511481A (ja) * | 2005-10-06 | 2009-03-19 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 増強された治療特性を持つ、胃H+,K+−ATPaseの重水素化阻害剤 |
US7576219B2 (en) | 2005-10-26 | 2009-08-18 | Hanmi Pharm. Co., Ltd | Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same |
JP2009518394A (ja) | 2005-12-05 | 2009-05-07 | アストラゼネカ・アクチエボラーグ | エソメプラゾールの非塩形態の新規の製造方法 |
EP1801110A1 (en) | 2005-12-22 | 2007-06-27 | KRKA, tovarna zdravil, d.d., Novo mesto | Esomeprazole arginine salt |
US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
ATE428707T1 (de) | 2005-12-28 | 2009-05-15 | Union Quimico Farma | Verfahren zur herstellung des (s)-enantiomers von omeprazol |
CA2634232C (en) | 2005-12-28 | 2013-08-20 | Takeda Pharmaceutical Company Limited | Method of producing solid preparation disintegrating in the oral cavity |
CN101453993A (zh) * | 2006-04-03 | 2009-06-10 | 伊萨·奥迪迪 | 含有机溶胶涂层的受控释放递送物件 |
US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
US7786309B2 (en) | 2006-06-09 | 2010-08-31 | Apotex Pharmachem Inc. | Process for the preparation of esomeprazole and salts thereof |
US7863330B2 (en) | 2006-06-14 | 2011-01-04 | Rottapharm S.P.A. | Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders |
PL2046334T3 (pl) | 2006-07-25 | 2015-02-27 | Vecta Ltd | Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI |
US20100317689A1 (en) * | 2006-09-19 | 2010-12-16 | Garst Michael E | Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety |
GB2444593B (en) | 2006-10-05 | 2010-06-09 | Santarus Inc | Novel formulations for immediate release of proton pump inhibitors and methods of using these formulations |
US20090092658A1 (en) * | 2007-10-05 | 2009-04-09 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
MX2009004475A (es) | 2006-10-27 | 2009-08-12 | Univ Missouri | Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma. |
EP3628307A1 (en) | 2006-12-22 | 2020-04-01 | Ironwood Pharmaceuticals, Inc. | Compositions comprising bile acid sequestrants for treating esophageal disorders |
EP1947099A1 (en) | 2007-01-18 | 2008-07-23 | LEK Pharmaceuticals D.D. | Process for solvent removal from omeprazole salts |
WO2008092939A2 (en) | 2007-01-31 | 2008-08-07 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation |
US20080194307A1 (en) * | 2007-02-13 | 2008-08-14 | Jeff Sanger | Sports-based game of chance |
EP2186807B1 (en) * | 2007-02-21 | 2015-01-07 | Cipla Limited | Process for the preparation of esomeprazole magnesium dihydrate |
CA2679741A1 (en) * | 2007-03-15 | 2008-09-18 | Sun Pharma Advanced Research Company Ltd. | Novel prodrugs |
ATE534643T1 (de) * | 2007-06-07 | 2011-12-15 | Aurobindo Pharma Ltd | Verbessertes verfahren zur herstellung eines optisch aktiven protonenpumpenhemmers |
EP2181106A1 (en) * | 2007-07-17 | 2010-05-05 | Ranbaxy Laboratories Limited | Process for the preparation op pantoprazole sodium and pantoprazole sodium sesquihydrate |
WO2009066317A2 (en) * | 2007-08-20 | 2009-05-28 | Macleods Pharmaceuticals Limited | Process for the preparation of pantoprazole sodium |
WO2009047775A2 (en) | 2007-10-08 | 2009-04-16 | Hetero Drugs Limited | Polymorphs of esomeprazole salts |
CN101450939B (zh) * | 2007-12-05 | 2013-06-19 | 沈阳药科大学 | 新型苯并咪唑类化合物 |
CA2716367C (en) | 2008-02-20 | 2015-05-26 | The Curators Of The University Of Missouri | Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same |
US8911787B2 (en) | 2008-02-26 | 2014-12-16 | Ranbaxy Laboratories Limited | Stable oral benzimidazole compositions and process of preparation thereof |
SG10201403986UA (en) * | 2008-04-15 | 2014-10-30 | Merck Sharp & Dohme | High Density Compositions Containing Posaconazole And Formulations Comprising The Same |
CA2720851A1 (en) * | 2008-04-15 | 2009-10-22 | Schering Corporation | Oral pharmaceutical compositions in a molecular solid dispersion |
KR101044880B1 (ko) * | 2008-06-12 | 2011-06-28 | 일양약품주식회사 | 항궤양제 화합물의 합성에 유용한 중간체의 제조방법 |
EP2147918A1 (en) | 2008-07-21 | 2010-01-27 | LEK Pharmaceuticals D.D. | Process for the preparation of S-omeprazole magnesium in a stable form |
CH699302B1 (de) * | 2008-08-11 | 2012-03-15 | Mepha Gmbh | Orale pharmazeutische Formulierung für Omeprazol, enthaltend eine spezifische Trennschicht. |
CA2736547C (en) | 2008-09-09 | 2016-11-01 | Pozen Inc. | Method for delivering a pharmaceutical composition to patient in need thereof |
EP2350044A4 (en) * | 2008-10-10 | 2012-06-06 | Celtaxsys Inc | PROCESS FOR INTRODUCTION OF NEGATIVE CHEMOTAXIS |
EP2264024A1 (en) | 2008-10-14 | 2010-12-22 | LEK Pharmaceuticals d.d. | Process for the preparation of enantiomerically enriched proton pump inhibitors |
WO2010134099A1 (en) | 2009-05-21 | 2010-11-25 | Cadila Healthcare Limited | One pot process for preparing omeprazole and related compounds |
CA2763373C (en) | 2009-05-27 | 2018-01-09 | Immunaid Pty Ltd | Methods and systems for determining preferred times for administering therapy to treat diseases |
MX2011013467A (es) | 2009-06-25 | 2012-02-13 | Astrazeneca Ab | Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine). |
EA021112B1 (ru) * | 2009-06-25 | 2015-04-30 | Поузен Инк. | Способ лечения боли и/или воспаления у пациента, нуждающегося в аспириновой терапии |
WO2011058569A1 (en) | 2009-11-12 | 2011-05-19 | Hetero Research Foundation | Process for the resolution of omeprazole |
WO2011080500A2 (en) | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
WO2011080502A2 (en) | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
EP2519229A2 (en) | 2009-12-29 | 2012-11-07 | Novartis AG | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
EP2345408A3 (en) | 2010-01-08 | 2012-02-29 | Dr. Reddy's Laboratories Ltd. | Acid labile drug formulations |
CN102140099A (zh) | 2010-02-02 | 2011-08-03 | 山东轩竹医药科技有限公司 | 新的吡啶衍生物 |
US9623622B2 (en) | 2010-02-24 | 2017-04-18 | Michael Baines | Packaging materials and methods |
WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
US9233103B2 (en) | 2011-03-25 | 2016-01-12 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy |
US20140343104A1 (en) | 2011-08-26 | 2014-11-20 | National University Corporation Nagoya University | Osteogenesis promoter and use thereof |
EP2862569A1 (en) | 2011-09-09 | 2015-04-22 | Cubist Pharmaceuticals, Inc. | Methods for treating intrapulmonary infections |
WO2013081566A1 (en) | 2011-11-25 | 2013-06-06 | Mahmut Bilgic | A formulation comprising benzimidazole |
EP2601947A1 (en) | 2011-12-05 | 2013-06-12 | Abo Bakr Mohammed Ali Al-Mehdar | Fixed-dose combination for treatment of helicobacter pylori associated diseases |
WO2013101897A2 (en) | 2011-12-28 | 2013-07-04 | Pozen Inc. | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
CN102584792B (zh) * | 2012-01-06 | 2014-06-11 | 南京优科生物医药研究有限公司 | 制备高纯度的埃索美拉唑盐的方法 |
CN104203938A (zh) | 2012-01-21 | 2014-12-10 | 朱比兰特生命科学有限公司 | 用于制备2-吡啶基甲基亚硫酰基苯并咪唑、它们的类似物和光学活性对映体的方法 |
US8809314B1 (en) | 2012-09-07 | 2014-08-19 | Cubist Pharmacueticals, Inc. | Cephalosporin compound |
US8476425B1 (en) | 2012-09-27 | 2013-07-02 | Cubist Pharmaceuticals, Inc. | Tazobactam arginine compositions |
ES2906114T3 (es) | 2013-01-15 | 2022-04-13 | Ironwood Pharmaceuticals Inc | Forma de dosificación oral gastrorretentiva de liberación sostenida de un secuestrante de ácidos biliares |
BR112015023523B8 (pt) | 2013-03-15 | 2023-03-07 | Merck Sharp & Dohme | Composições farmacêuticas e recipiente de forma de dosagem única |
US20140274993A1 (en) | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Ceftolozane-tazobactam pharmaceutical compositions |
US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
GB201306720D0 (en) | 2013-04-12 | 2013-05-29 | Special Products Ltd | Formulation |
AU2014233637A1 (en) | 2013-09-09 | 2015-03-26 | Merck Sharp & Dohme Corp. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
US20150094293A1 (en) | 2013-09-27 | 2015-04-02 | Calixa Therapeutics, Inc. | Solid forms of ceftolozane |
US9457011B2 (en) | 2014-02-25 | 2016-10-04 | Muslim D. Shahid | Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor |
FR3018812A1 (fr) | 2014-03-21 | 2015-09-25 | Minakem | Nouvelle phase intermediaire de la forme a du sel de magnesium dihydrate d'un enantiomere de l'omeprazole |
WO2015155281A1 (en) | 2014-04-11 | 2015-10-15 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical combinations of dabigatran and proton pump inhibitors |
WO2015155307A1 (en) | 2014-04-11 | 2015-10-15 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical combinations of rivaroxaban and proton pump inhibitors |
CN104045627A (zh) * | 2014-05-21 | 2014-09-17 | 丽珠医药集团股份有限公司 | 一种奥美拉唑纯化方法 |
US10548911B2 (en) | 2014-06-16 | 2020-02-04 | University Of Rochester | Small molecule anti-scarring agents |
US20180015118A1 (en) | 2015-02-03 | 2018-01-18 | Ironwood Pharmaceuticals, Inc. | Methods of treating upper gastrointestinal disorders in ppi refractory gerd |
WO2016174664A1 (en) | 2015-04-29 | 2016-11-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
WO2017145146A1 (en) | 2016-02-25 | 2017-08-31 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
KR102419769B1 (ko) * | 2016-08-11 | 2022-07-13 | 아다미스 파마슈티칼스 코포레이션 | 약물 조성물 |
EP3292862A1 (en) | 2016-09-07 | 2018-03-14 | Sandoz Ag | Omeprazole formulations |
US11370775B2 (en) * | 2016-09-14 | 2022-06-28 | Yufeng Jane Tseng | Substituted benzimidazole derivatives as D-amino acid oxidase (DAAO) inhibitors |
EP3720844A4 (en) | 2017-12-08 | 2021-08-11 | Adamis Pharmaceuticals Corporation | MEDICINAL COMPOSITIONS |
CN110317164B (zh) * | 2019-07-06 | 2022-08-19 | 抚州三和医药化工有限公司 | 一种奥美拉唑中间体的制备方法 |
EP4284374A1 (en) | 2021-01-29 | 2023-12-06 | Abbvie Inc. | Methods of administrating elagolix |
WO2024075017A1 (en) | 2022-10-04 | 2024-04-11 | Zabirnyk Arsenii | Inhibition of aortic valve calcification |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1234058A (ru) * | 1968-10-21 | 1971-06-03 | ||
SE418966B (sv) * | 1974-02-18 | 1981-07-06 | Haessle Ab | Analogiforfarande for framstellning av foreningar med magsyrasekretionsinhiberande verkan |
US4045564A (en) * | 1974-02-18 | 1977-08-30 | Ab Hassle | Benzimidazole derivatives useful as gastric acid secretion inhibitors |
SE416649B (sv) * | 1974-05-16 | 1981-01-26 | Haessle Ab | Forfarande for framstellning av foreningar som paverkar magsyrasekretionen |
IN148930B (ru) * | 1977-09-19 | 1981-07-25 | Hoffmann La Roche |
-
1978
- 1978-04-14 SE SE7804231A patent/SE7804231L/xx unknown
-
1979
- 1979-04-03 EP EP79850022A patent/EP0005129B1/en not_active Expired
- 1979-04-03 DE DE7979850022T patent/DE2960293D1/de not_active Expired
- 1979-04-03 CY CY1232A patent/CY1232A/xx unknown
- 1979-04-03 ZA ZA791586A patent/ZA791586B/xx unknown
- 1979-04-05 US US06/027,277 patent/US4255431A/en not_active Expired - Lifetime
- 1979-04-09 CA CA325,188A patent/CA1127158A/en not_active Expired
- 1979-04-10 NO NO791227A patent/NO152216C/no unknown
- 1979-04-11 DK DK151179A patent/DK150510C/da not_active IP Right Cessation
- 1979-04-12 FI FI791219A patent/FI65067C/fi not_active IP Right Cessation
- 1979-04-12 AT AT0290483A patent/AT389995B/de not_active IP Right Cessation
- 1979-04-12 DD DD79212192A patent/DD142882A5/de unknown
- 1979-04-12 AT AT0273279A patent/AT374471B/de not_active IP Right Cessation
- 1979-04-13 SU SU792751500A patent/SU895292A3/ru active
- 1979-04-13 HU HU79HE782A patent/HU179022B/hu unknown
- 1979-04-13 CS CS792549A patent/CS261851B2/cs unknown
- 1979-04-14 JP JP54044910A patent/JPS6034956B2/ja not_active Expired
- 1979-04-18 NZ NZ190203A patent/NZ190203A/xx unknown
- 1979-08-08 IE IE785/79A patent/IE48370B1/en not_active IP Right Cessation
-
1980
- 1980-01-18 SU SU802867805A patent/SU873879A3/ru active
- 1980-01-18 SU SU802870598A patent/SU878196A3/ru active
- 1980-01-18 SU SU802870599A patent/SU873880A3/ru active
- 1980-05-19 US US06/150,965 patent/US4337257A/en not_active Expired - Lifetime
-
1983
- 1983-04-06 US US06/482,513 patent/US4508905A/en not_active Expired - Lifetime
- 1983-04-21 JP JP58069319A patent/JPS58192880A/ja active Granted
- 1983-10-17 SG SG633/83A patent/SG63383G/en unknown
-
1984
- 1984-01-12 NO NO840112A patent/NO152785C/no unknown
- 1984-02-23 HK HK152/84A patent/HK15284A/xx not_active IP Right Cessation
-
1985
- 1985-12-30 MY MY74/85A patent/MY8500074A/xx unknown
-
1993
- 1993-06-16 LU LU88305C patent/LU88305I2/xx unknown
- 1993-06-16 LU LU88307C patent/LU88307I2/fr unknown
- 1993-06-16 NL NL930074C patent/NL930074I2/nl unknown
- 1993-06-16 NL NL930075C patent/NL930075I2/nl unknown
- 1993-09-06 LT LTRP937A patent/LT2274B/xx unknown
-
1994
- 1994-02-25 BG BG098597A patent/BG61492B2/bg unknown
- 1994-12-21 NO NO1994027C patent/NO1994027I1/no unknown
-
1995
- 1995-06-14 NO NO1995005C patent/NO1995005I1/no unknown
- 1995-06-14 NO NO1995006C patent/NO1995006I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU873879A3 (ru) | Способ получени производных бензимидазола или их солей | |
SU795476A3 (ru) | Способ получени производныхбЕНзиМидАзОлА или иХ СОлЕй | |
SU509221A3 (ru) | Способ получени 1,4-дигидро-пиридинов или их солей | |
SU727142A3 (ru) | Способ получени замещенных 1-сульфонилбензимидазолов | |
RU2163238C2 (ru) | Способ получения магниевой соли замещенного сульфинил-гетероциклического соединения | |
SU537626A3 (ru) | Способ получени производных алканоламина | |
SU1153829A3 (ru) | Способ получени 2-гуанидино-4-имидазотиазолов или их фармацевтически приемлемых аддитивных солей кислот | |
PL132249B1 (en) | Process for preparing novel derivatives of 2,4-dihydroxyhex-5-en-1-carboxylic acid | |
EP0181846B1 (en) | New substituted benzimidazoles, a process for their preparation and their use for inhibiting gastric acid secretion | |
SU873872A3 (ru) | Способ получени производных аминопропанола или их солей | |
NO159932B (no) | Fremgangsmaate for fremstilling av substituerte imidazolyl-tiazol-derivater. | |
CS274460B2 (en) | Method of 1-cyclopropyl-7-substituted-6-fluor-4-oxo-1,4-dihydroquinoline-3-carboxylic acid's derivatives production | |
EP0116628B1 (en) | 1-acyl-3-pyridylmethylguanidines and their use as antihypertensive agents | |
SU1222196A3 (ru) | Способ получени производных 2-аминометил-5-тиометилфурана | |
SU492076A3 (ru) | Способ получени замещенных гуанидина | |
SU656521A3 (ru) | Способ получени производных тиено(3,2-с) пиридина или их солей | |
SU1258325A3 (ru) | Способ получени производных @ -фталидил-5-фторурацила | |
SU795487A3 (ru) | Способ получени производных геллебри-гЕНиНА или иХ СОлЕй | |
EP1476441A1 (en) | A method of eliminating sulfone analog in the synthesis of pyridine-benzimidazole sulfoxides | |
SU1311621A3 (ru) | Способ получени 2-гуанидино-4-триазолил-тиазолов | |
SU683624A3 (ru) | Способ получени производных тиено-(3,2-с)пиридина или их солей | |
KR910008938B1 (ko) | 피리딘 유도체의 제조방법 | |
US2469554A (en) | The process of preparing the lactone of 2 methyl 3 hydroxy 4 carboxy 5 hydroxymethyl pyridine | |
US2568809A (en) | Tetrahalomethylhexestrols and derivatives thereof | |
EP0535528A1 (en) | Antibacterial 5-Nitro-1-methyl-imidazolyl-3-terbutyl-2-hydroxy-aryl-carbinols |